CHI’s Sixth Annual Leaders Biobanking Congress is being held September 15-17, 2014 in Seattle Washington.

NEEDHAM, MASSACHUSETTS, UNITED STATES, June 26, 2014 /EINPresswire.com/ -- NEEDHAM, MASS. Cambridge Healthtech Institute’s Sixth Annual Leaders in Biobanking Congress: Maximizing Your Investment in Biospecimens addresses both the business and science of biobanking, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting edge research.

Topics Include:

• Plenary Keynote Presentations on Defining Precision Medicine - It Takes a Village, - in which four speakers emphasize the diverse insights, broad resources and expansive collaborations needed to meet the promise of this field:
o Dr. Carolyn Compton of National Biomarkers Development Alliance and
o Arizona State University
o Dr. James Olson of Seattle Children's Hospital and Presage Biosciences
o Dr. Nathan Price of the Institute for Systems Biology
o Dr. John Slattery of University of Washington School of Medicine
• Biobanking Is a Business, which highlights costs, resource optimization, self-sustainability and other issues managers must consider to run successful biorepositories
• Informed Consent: Biosamples Start with Patients, which considers how to balance scientific utility with individual privacy, with examples on iPSC research, pediatric biobanking and unexpected results
• Putting Biosamples to Use, which emphasizes connections between good biobanking practices and biomarker development, translational research and personalized medicine
• Optimizing Value from Your Biospecimens, which offers insights on improving quality, biobanking informatics and global infrastructures for that purpose
• Biospecimen Processing and Storage Optimization, which explores temperature control, freeze-thaw effects, stabilization and other important factors that affect the quality of bio-and cryopreserved samples
• Case Study Presentations, which illustrate active Biobanker/Biouser Partnerships and each party's needs, contributions, bottlenecks and scientific results

Confirmed Speakers Include:

Cary D. Austin, M.D., Ph.D., D.A.B.P., Pathologist, Pathology, gRED, Genentech, Inc.

Geoffrey Baird, M.D., Ph.D., Assistant Professor, Laboratory Medicine, University of Washington

Stefano Begolo, Ph.D., Research Scientist, Rustem F. Ismagilov Laboratory, Division of Chemistry and Chemical Engineering, California Institute of Technology

Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

Wylie Burke, M.D., Ph.D., Professor, Bioethics and Humanities, University of Washington

Carolyn Compton, M.D., Ph.D., CMO, National Biomarkers Development Alliance and Professor,
School of Life Sciences, Arizona State University

Hoda Elgendy, Ph.D., CSO, BioActive Technologies, Inc.

Donna Farley, Associate Consultant, Eli Lilly and Company

Dayong Gao, Ph.D., Professor, Mechanical Engineering and Bioengineering, University of Washington

Allison Hubel, Ph.D., Professor, Mechanical Engineering and Director, Biopreservation Core Resource, University of Minnesota

Devon D. Kelly, Director, OHSU Knight BioLibrary, Oregon Health & Science University, Knight Cancer Institute

Bernard A. LaSalle, Director, Operations, BMIC, Biomedical Informatics, Center for Clinical and Translational Science, University of Utah

Sylvia M. Lee, M.D., Medical Oncologist, Seattle Cancer Care Alliance

Michael Liebman, Ph.D., Managing Director, IPQ Analytics, LLC

Geoffrey P. Lomax, Ph.D., Senior Officer, Standards Working Group, California Institute for Regenerative Medicine

James M. Olson, M.D., Ph.D., Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor, Pediatric Hematology and Oncology, University of Washington; Attending Physician, Seattle Children's Hospital; Founder, Presage Biosciences and Blaze Bioscience

Bruce Pharr, Vice President, Life Science Research Systems, Remedy Informatics

Nathan D. Price, Ph.D., Associate Director, Institute for Systems Biology

Shannon Sewards, Associate Director, Human Subjects Division, University of Washington

Stephen Schmechel, M.D., Ph.D., Associate Professor, UW Medicine Pathology, University of Washington

John T. Slattery, Ph.D., Vice Dean, Research and Graduate Education, School of Medicine and Professor, Pharmacology and Medicine, University of Washington School of Medicine

Stephanie Elaine Soares, MS, CCRP, Research Administrator, Urology, University of California Davis

Suzane Vercauteren, M.D., Ph.D., FRCPC, Head, Division of Hematopathology, BC Children's Hospital and Clinical Assistant Professor, Pathology and Laboratory Medicine, University of British Columbia

Amelia Wall Warner, President and CEO, Gentris

Wendell G. Yarbrough, M.D., MMHC, FACS, Professor of Surgery, Otolaryngology and Pathology; Section Chief, Otolaryngology; Co-Director, Molecular Virology Research Program; Director, Head and Neck Cancer Program, Smilow Cancer Hospital, Yale University

William H. Yong, M.D., Professor, Pathology and Laboratory Medicine, Neuropathologist, National Neurologic AIDS Bank Director, Brain Tumor Translational Resource David Geffen School of Medicine, University of California, Los Angeles

Claire Zhu, Ph.D., Program Director, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health

Early registration discounts are available until June 27th, 2014. To view the entire conference agenda and to register, please visit http://www.healthtech.com/biobanking.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Kerri Simpson
Cambridge Healthtech Institute
7819721347
email us here